Needham Downgrades Geron (GERN) to Hold
More News related to GERN
- Geron (GERN) Presents Interim Data from Imetelstat at AACR-NCI-EORTC Int. Conference
- Geron Presents Interim Clinical Data on Its Telomerase Inhibitor Drug at AACR-NCI-EORTC
- Geron to Present at LCM Healthcare Conference
- Trading Outlook for StemCells Inc. Issued by InvestorSoup.com
- Geron Corp. (GERN) Reports that hESC-Derived Oligodendrocyte Progenitor Cells Reduced Cervical Spinal Cord Injury
More News related to Downgrades
- Green Mountain (GMCR) Will Likely Win Diedrich Coffee (DDRX) Bidding War - Analyst
- FBR Capital Raises Estimates & PT on Trina Solar (TSL) following 3Q09 results
- Broadpoint.AmTech Reiterates a 'Buy' on Precision Castparts (PCP); Issues Top Ten for Owning Shares
- Citi Recommends Stocks in Qatar, UAE, Egypt; Believes Middle East Will 'Catch Up' to Emerging Markets
- Broadpoint.AmTech Maintains a 'Buy' on First Solar (FSLR); Lowers PT and Estimates
Needham & Co. downgrades Geron (Nasdaq: GERN) from Buy to Hold.
Visit our Analyst Ratings page to see all the upgrades/downgrades on shares of Geron.
Geron Corporation, a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes.
Related Categories
DowngradesStocks Mentioned
-0.05Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
